Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Triple -Negative Breast Cancer
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: Prospective, multicentric, single-arm, open label, phase IB clinical trial.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04494958
- Collaborators
- Pfizer
- Apices Soluciones S.L.
- Pierre Fabre Ibérica, S.A.
- Investigators
- Principal Investigator: Miguel Ángel Quintela-Fandino, MD Centro Nacional de Investigaciones Oncológicas
Get Well Soon